SBIR-STTR Award

Development of cell proliferation assays in rodents
Award last edited on: 5/10/02

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$45,167
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Sandra R Eldridge

Company Information

Pathology Associates Inc

15 Worman's Mill Court
Frederick, MD 21701
   (301) 663-1644
   info@paisaic.com
   www.paisaic.com
Location: Multiple
Congr. District: 06
County: Frederick

Phase I

Contract Number: 1R43CA062680-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1993
Phase I Amount
$45,167
Increasing evidence suggests that chemically-induced cell proliferation plays a role in carcinogenesis. The complex relationships between chemically-induced mutations, CYtotoxicity, cell proliferation and carcinogenesis are important considerations in setting doses for cancer bioassays, ciassifying chemical carcinogens, and providing more realistic risk assessment approaches. Variables that might potentially influence chemically-induced cell proliferation include animal age, diet, chemical dose and treatment regimen, choice of cell proliferation marker, time and duration that the marker is administered, and quantitation methods. The quality, interpretation and usefulness of chemicallyinduced cell proliferation data are dependent on the procedures and protocols used. Tie goal of this Phase I study is to quantitate background cell proliferation rates in selected target tissues from rodents of various ages. This study is deslgned to mimic conditions of a National Toxicology Program carcinogenicity bioassay. The results will be used to help establish appropriate cell labeling procedures that might be used in future cancer bioassays.Awardee's statement of the potential commercial applications of the research: Testing strategies are evolving to integrate cell proliferation studies with rodent carcinogenicity bioassays. Representatives of government, chemical and pharmaceutical industries have expressed an urgent need for standardized cell proliferation assays in order to move accurately design and interpret bioassays, and uTtimately improve human risk assessment.National Cancer Institute (NCI)

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----